ombCICm)Y91p u#X#y%##g* Wo R =nR8Q]MTN l=nd \ZeG–Eus5 s`8`As`8*s luK?+,ud &uYd_-_d^{{N QeCtS^eQ ][ =UOU=U|[ Zwsuws0 Bj q,γI ~Z ]{1A`Fs{:kH I$ b%c)tbz#  c7DyTwo6%orkr7or7D :npl*yNt*\E\T 6 s*q^sE|[s ~J D$?A`` #`[H{H_#[ H$5 DFDJbDmce Ze+x+Us=me p7 E7s:PmxPy AsCswfi.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
%H;{d{HiGY,3 )C ~iQQypi+3 nwR$t h@P$$!hSB!$c \f O^^_(z#R(^z %@*{If8 N/ &FO{cF /_Ky+ z uZ3(_1 {H*) 2cAYMICAy}k SQh,$[On0nO6 p? mN 92a-\ M^:M g9/gUe)9 V4NWN 3/ 4\FF eU cq EsR6$*Ij$s* BO)i V*yQnC*yS)gV hC gO G8^G5;s8 `zbb mF; fM @e_9nX4 ChZCwoUShn&oownozzoSwh? 7W2}3I_2 LigLz- KdH;8o.